Unknown PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00999349

Therapeutic Effects of Silymarin in Patients With B-thalassemia Major

Combined Therapy of Silymarin and Desferrioxamine in Patients With B-thalassemia Major: a Randomized Double-blind Clinical Trial

Sponsor: Isfahan University of Medical Sciences

Conditions Beta-thalassemia Major Iron Overload

Interventions Placebo Silymarin (LEGALON)

Updated 5 times since 2017 Last updated: Oct 20, 2009 Started: Mar 31, 2009 Primary completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Beta-thalassemia Major and Iron Overload, this trial is ongoing. The trial is conducted by Isfahan University of Medical Sciences and has accumulated 5 data snapshots since 2009. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2025 — Present [monthly]

Unknown PHASE2/PHASE3
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2/PHASE3

Status: Unknown Status → Unknown · Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2_PHASE3
Jan 2017 — Jan 2021 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Mar 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Isfahan University of Medical Sciences
Madaus Inc

Data source: Isfahan University of Medical Sciences

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Isfahan, Iran